Wockhardt, a pharmaceutical and biotechnology company, has received final FDA approval for marketing 100mg, 150mg and 200mg 12 hour extended release tablets of Bupropion HCl indicated for depression.

Wockhardt has announced the immediate launch of Bupropion, the generic version of Glaxo Smithkline's Wellbutrin SR, which it will manufacture at its facility in Waluj, India. The technology for the tablets was developed in-house.

Wockhardt founder chairman and group CEO Dr. Habil Khorakiwala said that the Bupropion SR 12-Hr is yet another product based on extended-release technology.

"Extended Release technology is a core competency of Wockhardt's R&D and they have consistently risen to the challenge of developing these technically challenging products," Khorakiwala added.

The total US market for the product is around $268m, according to IMS Health.